nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxorubicin—NOS2—psoriasis	0.316	1	CbGaD
Doxorubicin—NOS2—Dexamethasone—psoriasis	0.0555	0.143	CbGbCtD
Doxorubicin—ABCC10—Cyclosporine—psoriasis	0.037	0.0951	CbGbCtD
Doxorubicin—ABCC3—Cyclosporine—psoriasis	0.0232	0.0598	CbGbCtD
Doxorubicin—ABCB11—Cyclosporine—psoriasis	0.0201	0.0517	CbGbCtD
Doxorubicin—ABCC10—Methotrexate—psoriasis	0.0196	0.0503	CbGbCtD
Doxorubicin—ABCC1—Cyclosporine—psoriasis	0.0143	0.0367	CbGbCtD
Doxorubicin—ABCC2—Mycophenolate mofetil—psoriasis	0.0139	0.0359	CbGbCtD
Doxorubicin—CYP1B1—Dexamethasone—psoriasis	0.0132	0.034	CbGbCtD
Doxorubicin—ABCB11—Dexamethasone—psoriasis	0.0132	0.034	CbGbCtD
Doxorubicin—ABCG2—Mycophenolate mofetil—psoriasis	0.0126	0.0324	CbGbCtD
Doxorubicin—ABCC3—Methotrexate—psoriasis	0.0123	0.0316	CbGbCtD
Doxorubicin—ABCC2—Cyclosporine—psoriasis	0.0106	0.0272	CbGbCtD
Doxorubicin—CYP2B6—Cholecalciferol—psoriasis	0.0102	0.0263	CbGbCtD
Doxorubicin—ABCG2—Hydrocortisone—psoriasis	0.0101	0.026	CbGbCtD
Doxorubicin—ABCG2—Cyclosporine—psoriasis	0.00955	0.0246	CbGbCtD
Doxorubicin—CYP2D6—Hydroxyurea—psoriasis	0.00815	0.021	CbGbCtD
Doxorubicin—ABCC1—Methotrexate—psoriasis	0.00755	0.0194	CbGbCtD
Doxorubicin—ABCC2—Dexamethasone—psoriasis	0.00696	0.0179	CbGbCtD
Doxorubicin—ABCC6—dermis—psoriasis	0.00636	0.223	CbGeAlD
Doxorubicin—ABCG2—Dexamethasone—psoriasis	0.00629	0.0162	CbGbCtD
Doxorubicin—CYP3A4—Calcitriol—psoriasis	0.00609	0.0157	CbGbCtD
Doxorubicin—ABCC2—Methotrexate—psoriasis	0.00559	0.0144	CbGbCtD
Doxorubicin—ABCG2—Methotrexate—psoriasis	0.00505	0.013	CbGbCtD
Doxorubicin—CYP2D6—Cholecalciferol—psoriasis	0.00494	0.0127	CbGbCtD
Doxorubicin—CYP3A4—Methoxsalen—psoriasis	0.00474	0.0122	CbGbCtD
Doxorubicin—ABCB1—Mycophenolate mofetil—psoriasis	0.00454	0.0117	CbGbCtD
Doxorubicin—CYP2B6—Dexamethasone—psoriasis	0.00442	0.0114	CbGbCtD
Doxorubicin—ABCB1—Betamethasone—psoriasis	0.0039	0.01	CbGbCtD
Doxorubicin—ABCB1—Prednisolone—psoriasis	0.00385	0.00989	CbGbCtD
Doxorubicin—ABCB1—Hydrocortisone—psoriasis	0.00365	0.00938	CbGbCtD
Doxorubicin—ABCB1—Prednisone—psoriasis	0.00363	0.00934	CbGbCtD
Doxorubicin—ABCB1—Cyclosporine—psoriasis	0.00344	0.00886	CbGbCtD
Doxorubicin—CYP2D6—Cyclosporine—psoriasis	0.00324	0.00835	CbGbCtD
Doxorubicin—CYP3A4—Cholecalciferol—psoriasis	0.00314	0.00808	CbGbCtD
Doxorubicin—CYP3A4—Mycophenolate mofetil—psoriasis	0.00272	0.007	CbGbCtD
Doxorubicin—CYP3A4—Triamcinolone—psoriasis	0.00272	0.007	CbGbCtD
Doxorubicin—CYP3A4—Betamethasone—psoriasis	0.00234	0.00601	CbGbCtD
Doxorubicin—CYP3A4—Prednisolone—psoriasis	0.0023	0.00593	CbGbCtD
Doxorubicin—ABCB1—Dexamethasone—psoriasis	0.00227	0.00583	CbGbCtD
Doxorubicin—CYP3A4—Hydrocortisone—psoriasis	0.00218	0.00562	CbGbCtD
Doxorubicin—CYP3A4—Prednisone—psoriasis	0.00218	0.0056	CbGbCtD
Doxorubicin—CYP2D6—Dexamethasone—psoriasis	0.00214	0.0055	CbGbCtD
Doxorubicin—NOS1—endothelium—psoriasis	0.00213	0.0747	CbGeAlD
Doxorubicin—CYP3A4—Cyclosporine—psoriasis	0.00206	0.00531	CbGbCtD
Doxorubicin—NOS2—tendon—psoriasis	0.00191	0.0669	CbGeAlD
Doxorubicin—ABCB1—Methotrexate—psoriasis	0.00182	0.00469	CbGbCtD
Doxorubicin—NOS3—endothelium—psoriasis	0.00162	0.0568	CbGeAlD
Doxorubicin—CYP3A4—Dexamethasone—psoriasis	0.00136	0.00349	CbGbCtD
Doxorubicin—AKR1A1—skin of body—psoriasis	0.0012	0.0421	CbGeAlD
Doxorubicin—CBR3—tendon—psoriasis	0.00119	0.0415	CbGeAlD
Doxorubicin—AKR1A1—tendon—psoriasis	0.000915	0.0321	CbGeAlD
Doxorubicin—NDUFS2—skin of body—psoriasis	0.000906	0.0317	CbGeAlD
Doxorubicin—NDUFS3—skin of body—psoriasis	0.000895	0.0313	CbGeAlD
Doxorubicin—DHCR7—skin of body—psoriasis	0.00085	0.0298	CbGeAlD
Doxorubicin—NDUFS7—tendon—psoriasis	0.000832	0.0291	CbGeAlD
Doxorubicin—AURKA—tendon—psoriasis	0.000774	0.0271	CbGeAlD
Doxorubicin—NOS1—tendon—psoriasis	0.000694	0.0243	CbGeAlD
Doxorubicin—NDUFS2—tendon—psoriasis	0.000689	0.0241	CbGeAlD
Doxorubicin—NDUFS3—tendon—psoriasis	0.000681	0.0238	CbGeAlD
Doxorubicin—CBR1—skin of body—psoriasis	0.000658	0.023	CbGeAlD
Doxorubicin—YWHAG—tendon—psoriasis	0.000594	0.0208	CbGeAlD
Doxorubicin—RALBP1—tendon—psoriasis	0.000536	0.0188	CbGeAlD
Doxorubicin—NOS3—tendon—psoriasis	0.000527	0.0185	CbGeAlD
Doxorubicin—NQO1—skin of body—psoriasis	0.000527	0.0184	CbGeAlD
Doxorubicin—CBR1—tendon—psoriasis	0.000501	0.0175	CbGeAlD
Doxorubicin—AURKA—Mycophenolate mofetil—Mycophenolic acid—psoriasis	0.000499	0.137	CbGdCrCtD
Doxorubicin—AKR1C3—tendon—psoriasis	0.000494	0.0173	CbGeAlD
Doxorubicin—POR—tendon—psoriasis	0.000451	0.0158	CbGeAlD
Doxorubicin—TOP2A—tendon—psoriasis	0.000421	0.0147	CbGeAlD
Doxorubicin—NQO1—tendon—psoriasis	0.000401	0.014	CbGeAlD
Doxorubicin—CYP1B1—skin of body—psoriasis	0.00037	0.013	CbGeAlD
Doxorubicin—ABCC10—tendon—psoriasis	0.000358	0.0125	CbGeAlD
Doxorubicin—ABCC2—tendon—psoriasis	0.000288	0.0101	CbGeAlD
Doxorubicin—AURKA—Mycophenolic acid—Mycophenolate mofetil—psoriasis	0.000282	0.0775	CbGdCrCtD
Doxorubicin—CYP1B1—tendon—psoriasis	0.000282	0.00986	CbGeAlD
Doxorubicin—CYP2B6—skin of body—psoriasis	0.000254	0.0089	CbGeAlD
Doxorubicin—ABCC1—tendon—psoriasis	0.000253	0.00887	CbGeAlD
Doxorubicin—AURKA—Calcipotriol—Calcitriol—psoriasis	0.000165	0.0455	CbGdCrCtD
Doxorubicin—CBR3—Fluorometholone—Clobetasol propionate—psoriasis	0.000147	0.0404	CbGdCrCtD
Doxorubicin—AURKA—Calcipotriol—Cholecalciferol—psoriasis	0.000141	0.0387	CbGdCrCtD
Doxorubicin—CBR3—Triamcinolone—Clobetasol propionate—psoriasis	0.000121	0.0334	CbGdCrCtD
Doxorubicin—CBR3—Fluorometholone—Fluocinonide—psoriasis	0.000118	0.0324	CbGdCrCtD
Doxorubicin—CBR3—Fluorometholone—Beclomethasone—psoriasis	0.000118	0.0324	CbGdCrCtD
Doxorubicin—CBR3—Fluorometholone—Fluocinolone Acetonide—psoriasis	0.000114	0.0315	CbGdCrCtD
Doxorubicin—CBR3—Fluocinolone Acetonide—Clobetasol propionate—psoriasis	0.000112	0.0307	CbGdCrCtD
Doxorubicin—CBR3—Triamcinolone—Beclomethasone—psoriasis	9.72e-05	0.0267	CbGdCrCtD
Doxorubicin—CBR3—Triamcinolone—Fluocinonide—psoriasis	9.72e-05	0.0267	CbGdCrCtD
Doxorubicin—CBR3—Triamcinolone—Fluocinolone Acetonide—psoriasis	9.45e-05	0.026	CbGdCrCtD
Doxorubicin—CBR3—Fluocinolone Acetonide—Fluocinonide—psoriasis	8.93e-05	0.0246	CbGdCrCtD
Doxorubicin—CBR3—Fluocinolone Acetonide—Beclomethasone—psoriasis	8.93e-05	0.0246	CbGdCrCtD
Doxorubicin—CBR3—Dexamethasone—Clobetasol propionate—psoriasis	6e-05	0.0165	CbGdCrCtD
Doxorubicin—CBR3—Betamethasone—Clobetasol propionate—psoriasis	6e-05	0.0165	CbGdCrCtD
Doxorubicin—CBR3—Fluorometholone—Hydrocortisone—psoriasis	5.77e-05	0.0159	CbGdCrCtD
Doxorubicin—CBR3—Fluorometholone—Betamethasone—psoriasis	5.36e-05	0.0148	CbGdCrCtD
Doxorubicin—CBR3—Fluorometholone—Dexamethasone—psoriasis	5.36e-05	0.0148	CbGdCrCtD
Doxorubicin—CBR3—Fluorometholone—Triamcinolone—psoriasis	5.24e-05	0.0144	CbGdCrCtD
Doxorubicin—CBR3—Fluorometholone—Prednisone—psoriasis	4.97e-05	0.0137	CbGdCrCtD
Doxorubicin—CBR3—Fluorometholone—Prednisolone—psoriasis	4.85e-05	0.0134	CbGdCrCtD
Doxorubicin—CBR3—Dexamethasone—Fluocinonide—psoriasis	4.81e-05	0.0132	CbGdCrCtD
Doxorubicin—CBR3—Dexamethasone—Beclomethasone—psoriasis	4.81e-05	0.0132	CbGdCrCtD
Doxorubicin—CBR3—Betamethasone—Fluocinonide—psoriasis	4.81e-05	0.0132	CbGdCrCtD
Doxorubicin—CBR3—Betamethasone—Beclomethasone—psoriasis	4.81e-05	0.0132	CbGdCrCtD
Doxorubicin—CBR3—Triamcinolone—Hydrocortisone—psoriasis	4.77e-05	0.0131	CbGdCrCtD
Doxorubicin—CBR3—Betamethasone—Fluocinolone Acetonide—psoriasis	4.67e-05	0.0128	CbGdCrCtD
Doxorubicin—CBR3—Dexamethasone—Fluocinolone Acetonide—psoriasis	4.67e-05	0.0128	CbGdCrCtD
Doxorubicin—CBR3—Triamcinolone—Betamethasone—psoriasis	4.43e-05	0.0122	CbGdCrCtD
Doxorubicin—CBR3—Triamcinolone—Dexamethasone—psoriasis	4.43e-05	0.0122	CbGdCrCtD
Doxorubicin—CBR3—Triamcinolone—Prednisone—psoriasis	4.11e-05	0.0113	CbGdCrCtD
Doxorubicin—CBR3—Fluocinolone Acetonide—Dexamethasone—psoriasis	4.07e-05	0.0112	CbGdCrCtD
Doxorubicin—CBR3—Fluocinolone Acetonide—Betamethasone—psoriasis	4.07e-05	0.0112	CbGdCrCtD
Doxorubicin—CBR3—Triamcinolone—Prednisolone—psoriasis	4.01e-05	0.011	CbGdCrCtD
Doxorubicin—CBR3—Fluocinolone Acetonide—Triamcinolone—psoriasis	3.98e-05	0.0109	CbGdCrCtD
Doxorubicin—CBR3—Fluocinolone Acetonide—Prednisolone—psoriasis	3.69e-05	0.0101	CbGdCrCtD
Doxorubicin—XDH—Selenium Micronutrient Network—IL6—psoriasis	3.58e-05	0.000437	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—NDUFA5—psoriasis	3.56e-05	0.000435	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—TAGAP—psoriasis	3.54e-05	0.000433	CbGpPWpGaD
Doxorubicin—NOS1—Myometrial Relaxation and Contraction Pathways—IL6—psoriasis	3.53e-05	0.000431	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—HCAR2—psoriasis	3.45e-05	0.000422	CbGpPWpGaD
Doxorubicin—TOP2A—Circadian rythm related genes—PPARG—psoriasis	3.45e-05	0.000421	CbGpPWpGaD
Doxorubicin—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	3.44e-05	0.00042	CbGpPWpGaD
Doxorubicin—NOS3—Myometrial Relaxation and Contraction Pathways—JUN—psoriasis	3.42e-05	0.000418	CbGpPWpGaD
Doxorubicin—NOS1—Hemostasis—NOS2—psoriasis	3.42e-05	0.000418	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—NDUFA5—psoriasis	3.42e-05	0.000417	CbGpPWpGaD
Doxorubicin—CYP3A4—Tryptophan metabolism—CAT—psoriasis	3.37e-05	0.000411	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—IL10—psoriasis	3.35e-05	0.000409	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.32e-05	0.000406	CbGpPWpGaD
Doxorubicin—NOS2—Spinal Cord Injury—IL6—psoriasis	3.31e-05	0.000404	CbGpPWpGaD
Doxorubicin—NOS3—EGF/EGFR Signaling Pathway—JUN—psoriasis	3.3e-05	0.000403	CbGpPWpGaD
Doxorubicin—NOS3—Myometrial Relaxation and Contraction Pathways—NFKB1—psoriasis	3.3e-05	0.000402	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—IL4—psoriasis	3.26e-05	0.000397	CbGpPWpGaD
Doxorubicin—YWHAG—Apoptosis—TNF—psoriasis	3.23e-05	0.000394	CbGpPWpGaD
Doxorubicin—YWHAG—SIDS Susceptibility Pathways—TNF—psoriasis	3.21e-05	0.000392	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.19e-05	0.000389	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—HLA-B—psoriasis	3.18e-05	0.000389	CbGpPWpGaD
Doxorubicin—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	3.18e-05	0.000388	CbGpPWpGaD
Doxorubicin—ABCC3—Transmembrane transport of small molecules—CP—psoriasis	3.18e-05	0.000388	CbGpPWpGaD
Doxorubicin—ABCG2—HIF-1-alpha transcription factor network—VEGFA—psoriasis	3.18e-05	0.000387	CbGpPWpGaD
Doxorubicin—YWHAG—Cell Cycle, Mitotic—PCNA—psoriasis	3.17e-05	0.000387	CbGpPWpGaD
Doxorubicin—NDUFS3—Metabolism—CAT—psoriasis	3.16e-05	0.000386	CbGpPWpGaD
Doxorubicin—NDUFS7—Metabolism—CAT—psoriasis	3.16e-05	0.000386	CbGpPWpGaD
Doxorubicin—TOP2A—Retinoblastoma (RB) in Cancer—TP53—psoriasis	3.16e-05	0.000385	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—CYP2S1—psoriasis	3.03e-05	0.00037	CbGpPWpGaD
Doxorubicin—ABCC3—Transmembrane transport of small molecules—CARM1—psoriasis	3.03e-05	0.00037	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—TAGAP—psoriasis	3e-05	0.000365	CbGpPWpGaD
Doxorubicin—NDUFS2—Metabolism—CAT—psoriasis	2.97e-05	0.000363	CbGpPWpGaD
Doxorubicin—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	2.96e-05	0.000362	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—HLA-A—psoriasis	2.95e-05	0.00036	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—CYP2S1—psoriasis	2.91e-05	0.000355	CbGpPWpGaD
Doxorubicin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	2.9e-05	0.000354	CbGpPWpGaD
Doxorubicin—NOS3—EGF/EGFR Signaling Pathway—STAT3—psoriasis	2.86e-05	0.000349	CbGpPWpGaD
Doxorubicin—YWHAG—Apoptosis—TP53—psoriasis	2.84e-05	0.000347	CbGpPWpGaD
Doxorubicin—YWHAG—Cell Cycle—PCNA—psoriasis	2.83e-05	0.000346	CbGpPWpGaD
Doxorubicin—NOS3—VEGFA-VEGFR2 Pathway—IL6—psoriasis	2.78e-05	0.00034	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	2.7e-05	0.000329	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—NDUFA5—psoriasis	2.68e-05	0.000327	CbGpPWpGaD
Doxorubicin—NOS3—Signaling by VEGF—IL6—psoriasis	2.63e-05	0.000321	CbGpPWpGaD
Doxorubicin—YWHAG—Myometrial Relaxation and Contraction Pathways—IL6—psoriasis	2.6e-05	0.000318	CbGpPWpGaD
Doxorubicin—YWHAG—SIDS Susceptibility Pathways—IL6—psoriasis	2.59e-05	0.000316	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—NDUFA5—psoriasis	2.59e-05	0.000316	CbGpPWpGaD
Doxorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.55e-05	0.000311	CbGpPWpGaD
Doxorubicin—DHCR7—Metabolism—CAT—psoriasis	2.53e-05	0.000309	CbGpPWpGaD
Doxorubicin—ABCC2—Transmembrane transport of small molecules—CP—psoriasis	2.52e-05	0.000307	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.5e-05	0.000305	CbGpPWpGaD
Doxorubicin—ABCC1—Transmembrane transport of small molecules—CP—psoriasis	2.49e-05	0.000304	CbGpPWpGaD
Doxorubicin—NDUFS7—Metabolism—APOE—psoriasis	2.46e-05	0.0003	CbGpPWpGaD
Doxorubicin—NDUFS3—Metabolism—APOE—psoriasis	2.46e-05	0.0003	CbGpPWpGaD
Doxorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	2.45e-05	0.0003	CbGpPWpGaD
Doxorubicin—TOP2A—Circadian rythm related genes—JUN—psoriasis	2.45e-05	0.000299	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.41e-05	0.000295	CbGpPWpGaD
Doxorubicin—ABCC2—Transmembrane transport of small molecules—CARM1—psoriasis	2.4e-05	0.000293	CbGpPWpGaD
Doxorubicin—ABCC1—Transmembrane transport of small molecules—CARM1—psoriasis	2.37e-05	0.00029	CbGpPWpGaD
Doxorubicin—NOS2—Circadian rythm related genes—TP53—psoriasis	2.36e-05	0.000288	CbGpPWpGaD
Doxorubicin—CBR3—Betamethasone—Hydrocortisone—psoriasis	2.36e-05	0.00649	CbGdCrCtD
Doxorubicin—CBR3—Dexamethasone—Hydrocortisone—psoriasis	2.36e-05	0.00649	CbGdCrCtD
Doxorubicin—CBR1—Metabolism—CAT—psoriasis	2.36e-05	0.000288	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—NDUFA5—psoriasis	2.36e-05	0.000287	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.32e-05	0.000283	CbGpPWpGaD
Doxorubicin—NDUFS2—Metabolism—APOE—psoriasis	2.31e-05	0.000282	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—CYP2S1—psoriasis	2.28e-05	0.000278	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—CARM1—psoriasis	2.24e-05	0.000273	CbGpPWpGaD
Doxorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	2.23e-05	0.000272	CbGpPWpGaD
Doxorubicin—TOP2A—Cell Cycle, Mitotic—PCNA—psoriasis	2.22e-05	0.00027	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—CYP2S1—psoriasis	2.2e-05	0.000269	CbGpPWpGaD
Doxorubicin—CBR3—Dexamethasone—Betamethasone—psoriasis	2.19e-05	0.00603	CbGdCrCtD
Doxorubicin—CBR3—Betamethasone—Dexamethasone—psoriasis	2.19e-05	0.00603	CbGdCrCtD
Doxorubicin—ABCG2—Transmembrane transport of small molecules—CP—psoriasis	2.19e-05	0.000267	CbGpPWpGaD
Doxorubicin—Dermatitis—Mycophenolic acid—psoriasis	2.18e-05	0.000121	CcSEcCtD
Doxorubicin—Pain—Prednisolone—psoriasis	2.18e-05	0.000121	CcSEcCtD
Doxorubicin—Hepatitis—Methotrexate—psoriasis	2.18e-05	0.00012	CcSEcCtD
Doxorubicin—Haemorrhage—Methotrexate—psoriasis	2.18e-05	0.00012	CcSEcCtD
Doxorubicin—Urticaria—Mycophenolate mofetil—psoriasis	2.17e-05	0.00012	CcSEcCtD
Doxorubicin—Headache—Mycophenolic acid—psoriasis	2.17e-05	0.00012	CcSEcCtD
Doxorubicin—Decreased appetite—Hydrocortisone—psoriasis	2.17e-05	0.00012	CcSEcCtD
Doxorubicin—Pharyngitis—Methotrexate—psoriasis	2.17e-05	0.00012	CcSEcCtD
Doxorubicin—NOS2—Circadian rythm related genes—IL6—psoriasis	2.16e-05	0.000264	CbGpPWpGaD
Doxorubicin—Abdominal pain—Mycophenolate mofetil—psoriasis	2.16e-05	0.000119	CcSEcCtD
Doxorubicin—Body temperature increased—Mycophenolate mofetil—psoriasis	2.16e-05	0.000119	CcSEcCtD
Doxorubicin—AKR1C3—Metabolism—CARM1—psoriasis	2.16e-05	0.000264	CbGpPWpGaD
Doxorubicin—Urinary tract disorder—Methotrexate—psoriasis	2.15e-05	0.000119	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Hydrocortisone—psoriasis	2.15e-05	0.000119	CcSEcCtD
Doxorubicin—Fatigue—Hydrocortisone—psoriasis	2.15e-05	0.000119	CcSEcCtD
Doxorubicin—Vision blurred—Prednisone—psoriasis	2.14e-05	0.000118	CcSEcCtD
Doxorubicin—NDUFS7—Metabolism—PPARG—psoriasis	2.14e-05	0.000261	CbGpPWpGaD
Doxorubicin—NDUFS3—Metabolism—PPARG—psoriasis	2.14e-05	0.000261	CbGpPWpGaD
Doxorubicin—CBR3—Dexamethasone—Triamcinolone—psoriasis	2.14e-05	0.00589	CbGdCrCtD
Doxorubicin—CBR3—Betamethasone—Triamcinolone—psoriasis	2.14e-05	0.00589	CbGdCrCtD
Doxorubicin—Urethral disorder—Methotrexate—psoriasis	2.14e-05	0.000118	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Triamcinolone—psoriasis	2.14e-05	0.000118	CcSEcCtD
Doxorubicin—Pain—Hydrocortisone—psoriasis	2.13e-05	0.000118	CcSEcCtD
Doxorubicin—Oedema—Dexamethasone—psoriasis	2.13e-05	0.000118	CcSEcCtD
Doxorubicin—Oedema—Betamethasone—psoriasis	2.13e-05	0.000118	CcSEcCtD
Doxorubicin—Anaphylactic shock—Betamethasone—psoriasis	2.13e-05	0.000118	CcSEcCtD
Doxorubicin—Anaphylactic shock—Dexamethasone—psoriasis	2.13e-05	0.000118	CcSEcCtD
Doxorubicin—AKR1C3—Signaling Pathways—CCL20—psoriasis	2.12e-05	0.000259	CbGpPWpGaD
Doxorubicin—Insomnia—Triamcinolone—psoriasis	2.12e-05	0.000117	CcSEcCtD
Doxorubicin—Infection—Betamethasone—psoriasis	2.12e-05	0.000117	CcSEcCtD
Doxorubicin—Infection—Dexamethasone—psoriasis	2.12e-05	0.000117	CcSEcCtD
Doxorubicin—RALBP1—Signaling Pathways—SOCS1—psoriasis	2.11e-05	0.000258	CbGpPWpGaD
Doxorubicin—Ill-defined disorder—Prednisone—psoriasis	2.11e-05	0.000116	CcSEcCtD
Doxorubicin—Paraesthesia—Triamcinolone—psoriasis	2.11e-05	0.000116	CcSEcCtD
Doxorubicin—Feeling abnormal—Prednisolone—psoriasis	2.1e-05	0.000116	CcSEcCtD
Doxorubicin—Visual impairment—Methotrexate—psoriasis	2.1e-05	0.000116	CcSEcCtD
Doxorubicin—Anaemia—Prednisone—psoriasis	2.1e-05	0.000116	CcSEcCtD
Doxorubicin—Shock—Betamethasone—psoriasis	2.1e-05	0.000116	CcSEcCtD
Doxorubicin—Shock—Dexamethasone—psoriasis	2.1e-05	0.000116	CcSEcCtD
Doxorubicin—Dyspnoea—Triamcinolone—psoriasis	2.09e-05	0.000116	CcSEcCtD
Doxorubicin—ABCG2—Transmembrane transport of small molecules—CARM1—psoriasis	2.09e-05	0.000255	CbGpPWpGaD
Doxorubicin—Nervous system disorder—Dexamethasone—psoriasis	2.09e-05	0.000115	CcSEcCtD
Doxorubicin—Nervous system disorder—Betamethasone—psoriasis	2.09e-05	0.000115	CcSEcCtD
Doxorubicin—Agitation—Prednisone—psoriasis	2.09e-05	0.000115	CcSEcCtD
Doxorubicin—Thrombocytopenia—Dexamethasone—psoriasis	2.09e-05	0.000115	CcSEcCtD
Doxorubicin—Thrombocytopenia—Betamethasone—psoriasis	2.09e-05	0.000115	CcSEcCtD
Doxorubicin—Tachycardia—Betamethasone—psoriasis	2.08e-05	0.000115	CcSEcCtD
Doxorubicin—Tachycardia—Dexamethasone—psoriasis	2.08e-05	0.000115	CcSEcCtD
Doxorubicin—NOS3—Myometrial Relaxation and Contraction Pathways—IL6—psoriasis	2.07e-05	0.000252	CbGpPWpGaD
Doxorubicin—Hypersensitivity—Cyclosporine—psoriasis	2.07e-05	0.000114	CcSEcCtD
Doxorubicin—Dyspepsia—Triamcinolone—psoriasis	2.07e-05	0.000114	CcSEcCtD
Doxorubicin—Erythema multiforme—Methotrexate—psoriasis	2.06e-05	0.000114	CcSEcCtD
Doxorubicin—Nausea—Mycophenolic acid—psoriasis	2.06e-05	0.000114	CcSEcCtD
Doxorubicin—Hyperhidrosis—Dexamethasone—psoriasis	2.06e-05	0.000114	CcSEcCtD
Doxorubicin—Hyperhidrosis—Betamethasone—psoriasis	2.06e-05	0.000114	CcSEcCtD
Doxorubicin—Feeling abnormal—Hydrocortisone—psoriasis	2.05e-05	0.000113	CcSEcCtD
Doxorubicin—Malaise—Prednisone—psoriasis	2.05e-05	0.000113	CcSEcCtD
Doxorubicin—Vertigo—Prednisone—psoriasis	2.04e-05	0.000113	CcSEcCtD
Doxorubicin—Eye disorder—Methotrexate—psoriasis	2.04e-05	0.000113	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Hydrocortisone—psoriasis	2.04e-05	0.000113	CcSEcCtD
Doxorubicin—Syncope—Prednisone—psoriasis	2.04e-05	0.000113	CcSEcCtD
Doxorubicin—Tinnitus—Methotrexate—psoriasis	2.03e-05	0.000112	CcSEcCtD
Doxorubicin—CBR3—Dexamethasone—Prednisone—psoriasis	2.03e-05	0.00559	CbGdCrCtD
Doxorubicin—CBR3—Betamethasone—Prednisone—psoriasis	2.03e-05	0.00559	CbGdCrCtD
Doxorubicin—Anorexia—Dexamethasone—psoriasis	2.03e-05	0.000112	CcSEcCtD
Doxorubicin—Anorexia—Betamethasone—psoriasis	2.03e-05	0.000112	CcSEcCtD
Doxorubicin—Urticaria—Prednisolone—psoriasis	2.03e-05	0.000112	CcSEcCtD
Doxorubicin—Cardiac disorder—Methotrexate—psoriasis	2.02e-05	0.000112	CcSEcCtD
Doxorubicin—Fatigue—Triamcinolone—psoriasis	2.02e-05	0.000112	CcSEcCtD
Doxorubicin—AKR1C3—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.02e-05	0.000246	CbGpPWpGaD
Doxorubicin—Hypersensitivity—Mycophenolate mofetil—psoriasis	2.02e-05	0.000111	CcSEcCtD
Doxorubicin—Asthenia—Cyclosporine—psoriasis	2.01e-05	0.000111	CcSEcCtD
Doxorubicin—NDUFS2—Metabolism—PPARG—psoriasis	2.01e-05	0.000246	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—CARM1—psoriasis	2.01e-05	0.000245	CbGpPWpGaD
Doxorubicin—Pain—Triamcinolone—psoriasis	2.01e-05	0.000111	CcSEcCtD
Doxorubicin—NOS3—Hemostasis—NOS2—psoriasis	2e-05	0.000245	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—CYP2S1—psoriasis	2e-05	0.000244	CbGpPWpGaD
Doxorubicin—Loss of consciousness—Prednisone—psoriasis	2e-05	0.00011	CcSEcCtD
Doxorubicin—Hypotension—Betamethasone—psoriasis	1.99e-05	0.00011	CcSEcCtD
Doxorubicin—Hypotension—Dexamethasone—psoriasis	1.99e-05	0.00011	CcSEcCtD
Doxorubicin—Pruritus—Cyclosporine—psoriasis	1.98e-05	0.00011	CcSEcCtD
Doxorubicin—CBR3—Dexamethasone—Prednisolone—psoriasis	1.98e-05	0.00545	CbGdCrCtD
Doxorubicin—CBR3—Betamethasone—Prednisolone—psoriasis	1.98e-05	0.00545	CbGdCrCtD
Doxorubicin—NOS1—Hemostasis—VEGFA—psoriasis	1.98e-05	0.000242	CbGpPWpGaD
Doxorubicin—TOP2A—Cell Cycle—PCNA—psoriasis	1.98e-05	0.000242	CbGpPWpGaD
Doxorubicin—Urticaria—Hydrocortisone—psoriasis	1.98e-05	0.000109	CcSEcCtD
Doxorubicin—Angiopathy—Methotrexate—psoriasis	1.98e-05	0.000109	CcSEcCtD
Doxorubicin—Immune system disorder—Methotrexate—psoriasis	1.97e-05	0.000109	CcSEcCtD
Doxorubicin—Body temperature increased—Hydrocortisone—psoriasis	1.97e-05	0.000109	CcSEcCtD
Doxorubicin—Abdominal pain—Hydrocortisone—psoriasis	1.97e-05	0.000109	CcSEcCtD
Doxorubicin—Convulsion—Prednisone—psoriasis	1.97e-05	0.000109	CcSEcCtD
Doxorubicin—ABCB1—Allograft Rejection—IFNG—psoriasis	1.97e-05	0.00024	CbGpPWpGaD
Doxorubicin—Mediastinal disorder—Methotrexate—psoriasis	1.97e-05	0.000109	CcSEcCtD
Doxorubicin—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	1.96e-05	0.00024	CbGpPWpGaD
Doxorubicin—DHCR7—Metabolism—APOE—psoriasis	1.96e-05	0.00024	CbGpPWpGaD
Doxorubicin—Asthenia—Mycophenolate mofetil—psoriasis	1.96e-05	0.000108	CcSEcCtD
Doxorubicin—Hypertension—Prednisone—psoriasis	1.96e-05	0.000108	CcSEcCtD
Doxorubicin—Chills—Methotrexate—psoriasis	1.96e-05	0.000108	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Betamethasone—psoriasis	1.94e-05	0.000107	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Dexamethasone—psoriasis	1.94e-05	0.000107	CcSEcCtD
Doxorubicin—Pruritus—Mycophenolate mofetil—psoriasis	1.94e-05	0.000107	CcSEcCtD
Doxorubicin—Myalgia—Prednisone—psoriasis	1.93e-05	0.000107	CcSEcCtD
Doxorubicin—Arthralgia—Prednisone—psoriasis	1.93e-05	0.000107	CcSEcCtD
Doxorubicin—Feeling abnormal—Triamcinolone—psoriasis	1.93e-05	0.000107	CcSEcCtD
Doxorubicin—Anxiety—Prednisone—psoriasis	1.93e-05	0.000106	CcSEcCtD
Doxorubicin—Alopecia—Methotrexate—psoriasis	1.93e-05	0.000106	CcSEcCtD
Doxorubicin—Insomnia—Betamethasone—psoriasis	1.93e-05	0.000106	CcSEcCtD
Doxorubicin—Insomnia—Dexamethasone—psoriasis	1.93e-05	0.000106	CcSEcCtD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	1.92e-05	0.000106	CcSEcCtD
Doxorubicin—Diarrhoea—Cyclosporine—psoriasis	1.92e-05	0.000106	CcSEcCtD
Doxorubicin—Paraesthesia—Betamethasone—psoriasis	1.91e-05	0.000106	CcSEcCtD
Doxorubicin—Paraesthesia—Dexamethasone—psoriasis	1.91e-05	0.000106	CcSEcCtD
Doxorubicin—Discomfort—Prednisone—psoriasis	1.91e-05	0.000106	CcSEcCtD
Doxorubicin—Mental disorder—Methotrexate—psoriasis	1.91e-05	0.000106	CcSEcCtD
Doxorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.91e-05	0.000233	CbGpPWpGaD
Doxorubicin—NOS1—Disease—HLA-A—psoriasis	1.9e-05	0.000232	CbGpPWpGaD
Doxorubicin—Malnutrition—Methotrexate—psoriasis	1.9e-05	0.000105	CcSEcCtD
Doxorubicin—Erythema—Methotrexate—psoriasis	1.9e-05	0.000105	CcSEcCtD
Doxorubicin—Hypersensitivity—Prednisolone—psoriasis	1.88e-05	0.000104	CcSEcCtD
Doxorubicin—Dyspepsia—Dexamethasone—psoriasis	1.87e-05	0.000104	CcSEcCtD
Doxorubicin—Dyspepsia—Betamethasone—psoriasis	1.87e-05	0.000104	CcSEcCtD
Doxorubicin—Diarrhoea—Mycophenolate mofetil—psoriasis	1.87e-05	0.000103	CcSEcCtD
Doxorubicin—Urticaria—Triamcinolone—psoriasis	1.86e-05	0.000103	CcSEcCtD
Doxorubicin—Dysgeusia—Methotrexate—psoriasis	1.86e-05	0.000103	CcSEcCtD
Doxorubicin—Body temperature increased—Triamcinolone—psoriasis	1.86e-05	0.000102	CcSEcCtD
Doxorubicin—Dizziness—Cyclosporine—psoriasis	1.85e-05	0.000102	CcSEcCtD
Doxorubicin—Anaphylactic shock—Prednisone—psoriasis	1.85e-05	0.000102	CcSEcCtD
Doxorubicin—Oedema—Prednisone—psoriasis	1.85e-05	0.000102	CcSEcCtD
Doxorubicin—Decreased appetite—Dexamethasone—psoriasis	1.85e-05	0.000102	CcSEcCtD
Doxorubicin—Decreased appetite—Betamethasone—psoriasis	1.85e-05	0.000102	CcSEcCtD
Doxorubicin—Infection—Prednisone—psoriasis	1.84e-05	0.000102	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Dexamethasone—psoriasis	1.84e-05	0.000102	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Betamethasone—psoriasis	1.84e-05	0.000102	CcSEcCtD
Doxorubicin—Back pain—Methotrexate—psoriasis	1.84e-05	0.000101	CcSEcCtD
Doxorubicin—Hypersensitivity—Hydrocortisone—psoriasis	1.84e-05	0.000101	CcSEcCtD
Doxorubicin—Fatigue—Dexamethasone—psoriasis	1.84e-05	0.000101	CcSEcCtD
Doxorubicin—Fatigue—Betamethasone—psoriasis	1.84e-05	0.000101	CcSEcCtD
Doxorubicin—CBR1—Metabolism—APOE—psoriasis	1.83e-05	0.000224	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—CXCL8—psoriasis	1.83e-05	0.000223	CbGpPWpGaD
Doxorubicin—Shock—Prednisone—psoriasis	1.82e-05	0.000101	CcSEcCtD
Doxorubicin—NOS3—Metabolism—CARM1—psoriasis	1.82e-05	0.000223	CbGpPWpGaD
Doxorubicin—Pain—Betamethasone—psoriasis	1.82e-05	0.000101	CcSEcCtD
Doxorubicin—Pain—Dexamethasone—psoriasis	1.82e-05	0.000101	CcSEcCtD
Doxorubicin—Nervous system disorder—Prednisone—psoriasis	1.82e-05	0.0001	CcSEcCtD
Doxorubicin—Tachycardia—Prednisone—psoriasis	1.81e-05	0.0001	CcSEcCtD
Doxorubicin—Dizziness—Mycophenolate mofetil—psoriasis	1.81e-05	9.99e-05	CcSEcCtD
Doxorubicin—Skin disorder—Prednisone—psoriasis	1.8e-05	9.95e-05	CcSEcCtD
Doxorubicin—NOS3—Signaling Pathways—CCL20—psoriasis	1.79e-05	0.000219	CbGpPWpGaD
Doxorubicin—Hyperhidrosis—Prednisone—psoriasis	1.79e-05	9.9e-05	CcSEcCtD
Doxorubicin—Vision blurred—Methotrexate—psoriasis	1.79e-05	9.88e-05	CcSEcCtD
Doxorubicin—Asthenia—Hydrocortisone—psoriasis	1.79e-05	9.88e-05	CcSEcCtD
Doxorubicin—Vomiting—Cyclosporine—psoriasis	1.78e-05	9.85e-05	CcSEcCtD
Doxorubicin—NOS1—Disease—APOE—psoriasis	1.78e-05	0.000217	CbGpPWpGaD
Doxorubicin—Rash—Cyclosporine—psoriasis	1.77e-05	9.77e-05	CcSEcCtD
Doxorubicin—Anorexia—Prednisone—psoriasis	1.77e-05	9.76e-05	CcSEcCtD
Doxorubicin—Dermatitis—Cyclosporine—psoriasis	1.77e-05	9.76e-05	CcSEcCtD
Doxorubicin—Pruritus—Hydrocortisone—psoriasis	1.76e-05	9.74e-05	CcSEcCtD
Doxorubicin—Ill-defined disorder—Methotrexate—psoriasis	1.76e-05	9.73e-05	CcSEcCtD
Doxorubicin—Headache—Cyclosporine—psoriasis	1.76e-05	9.7e-05	CcSEcCtD
Doxorubicin—Anaemia—Methotrexate—psoriasis	1.76e-05	9.69e-05	CcSEcCtD
Doxorubicin—Feeling abnormal—Dexamethasone—psoriasis	1.76e-05	9.69e-05	CcSEcCtD
Doxorubicin—Feeling abnormal—Betamethasone—psoriasis	1.76e-05	9.69e-05	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Betamethasone—psoriasis	1.74e-05	9.62e-05	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Dexamethasone—psoriasis	1.74e-05	9.62e-05	CcSEcCtD
Doxorubicin—Vomiting—Mycophenolate mofetil—psoriasis	1.74e-05	9.61e-05	CcSEcCtD
Doxorubicin—Hypersensitivity—Triamcinolone—psoriasis	1.73e-05	9.55e-05	CcSEcCtD
Doxorubicin—CYP2B6—Metabolism—NDUFA5—psoriasis	1.73e-05	0.000211	CbGpPWpGaD
Doxorubicin—Rash—Mycophenolate mofetil—psoriasis	1.73e-05	9.53e-05	CcSEcCtD
Doxorubicin—Dermatitis—Mycophenolate mofetil—psoriasis	1.72e-05	9.52e-05	CcSEcCtD
Doxorubicin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	1.72e-05	0.000209	CbGpPWpGaD
Doxorubicin—Headache—Mycophenolate mofetil—psoriasis	1.71e-05	9.47e-05	CcSEcCtD
Doxorubicin—Malaise—Methotrexate—psoriasis	1.71e-05	9.46e-05	CcSEcCtD
Doxorubicin—DHCR7—Metabolism—PPARG—psoriasis	1.71e-05	0.000209	CbGpPWpGaD
Doxorubicin—Vertigo—Methotrexate—psoriasis	1.71e-05	9.42e-05	CcSEcCtD
Doxorubicin—Diarrhoea—Hydrocortisone—psoriasis	1.71e-05	9.42e-05	CcSEcCtD
Doxorubicin—Leukopenia—Methotrexate—psoriasis	1.7e-05	9.39e-05	CcSEcCtD
Doxorubicin—Urticaria—Betamethasone—psoriasis	1.69e-05	9.34e-05	CcSEcCtD
Doxorubicin—Urticaria—Dexamethasone—psoriasis	1.69e-05	9.34e-05	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Prednisone—psoriasis	1.69e-05	9.33e-05	CcSEcCtD
Doxorubicin—Dizziness—Prednisolone—psoriasis	1.69e-05	9.32e-05	CcSEcCtD
Doxorubicin—Asthenia—Triamcinolone—psoriasis	1.68e-05	9.3e-05	CcSEcCtD
Doxorubicin—Abdominal pain—Betamethasone—psoriasis	1.68e-05	9.3e-05	CcSEcCtD
Doxorubicin—Abdominal pain—Dexamethasone—psoriasis	1.68e-05	9.3e-05	CcSEcCtD
Doxorubicin—Body temperature increased—Betamethasone—psoriasis	1.68e-05	9.3e-05	CcSEcCtD
Doxorubicin—Body temperature increased—Dexamethasone—psoriasis	1.68e-05	9.3e-05	CcSEcCtD
Doxorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.68e-05	0.000205	CbGpPWpGaD
Doxorubicin—Insomnia—Prednisone—psoriasis	1.68e-05	9.26e-05	CcSEcCtD
Doxorubicin—Nausea—Cyclosporine—psoriasis	1.67e-05	9.2e-05	CcSEcCtD
Doxorubicin—Paraesthesia—Prednisone—psoriasis	1.67e-05	9.2e-05	CcSEcCtD
Doxorubicin—Pruritus—Triamcinolone—psoriasis	1.66e-05	9.17e-05	CcSEcCtD
Doxorubicin—Cough—Methotrexate—psoriasis	1.66e-05	9.15e-05	CcSEcCtD
Doxorubicin—NOS1—Disease—NOS2—psoriasis	1.66e-05	0.000202	CbGpPWpGaD
Doxorubicin—Dizziness—Hydrocortisone—psoriasis	1.65e-05	9.1e-05	CcSEcCtD
Doxorubicin—Convulsion—Methotrexate—psoriasis	1.65e-05	9.09e-05	CcSEcCtD
Doxorubicin—Dyspepsia—Prednisone—psoriasis	1.63e-05	9.02e-05	CcSEcCtD
Doxorubicin—Nausea—Mycophenolate mofetil—psoriasis	1.63e-05	8.98e-05	CcSEcCtD
Doxorubicin—Arthralgia—Methotrexate—psoriasis	1.62e-05	8.93e-05	CcSEcCtD
Doxorubicin—Myalgia—Methotrexate—psoriasis	1.62e-05	8.93e-05	CcSEcCtD
Doxorubicin—Chest pain—Methotrexate—psoriasis	1.62e-05	8.93e-05	CcSEcCtD
Doxorubicin—TOP2A—Circadian rythm related genes—TP53—psoriasis	1.62e-05	0.000197	CbGpPWpGaD
Doxorubicin—Decreased appetite—Prednisone—psoriasis	1.61e-05	8.9e-05	CcSEcCtD
Doxorubicin—Rash—Prednisolone—psoriasis	1.61e-05	8.89e-05	CcSEcCtD
Doxorubicin—Dermatitis—Prednisolone—psoriasis	1.61e-05	8.88e-05	CcSEcCtD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	1.61e-05	8.87e-05	CcSEcCtD
Doxorubicin—Fatigue—Prednisone—psoriasis	1.6e-05	8.83e-05	CcSEcCtD
Doxorubicin—Headache—Prednisolone—psoriasis	1.6e-05	8.83e-05	CcSEcCtD
Doxorubicin—Discomfort—Methotrexate—psoriasis	1.6e-05	8.82e-05	CcSEcCtD
Doxorubicin—CBR1—Metabolism—PPARG—psoriasis	1.6e-05	0.000195	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.59e-05	0.000194	CbGpPWpGaD
Doxorubicin—Constipation—Prednisone—psoriasis	1.59e-05	8.76e-05	CcSEcCtD
Doxorubicin—Vomiting—Hydrocortisone—psoriasis	1.59e-05	8.75e-05	CcSEcCtD
Doxorubicin—Rash—Hydrocortisone—psoriasis	1.57e-05	8.68e-05	CcSEcCtD
Doxorubicin—Dermatitis—Hydrocortisone—psoriasis	1.57e-05	8.67e-05	CcSEcCtD
Doxorubicin—Confusional state—Methotrexate—psoriasis	1.56e-05	8.63e-05	CcSEcCtD
Doxorubicin—Headache—Hydrocortisone—psoriasis	1.56e-05	8.62e-05	CcSEcCtD
Doxorubicin—RALBP1—Signaling Pathways—APOE—psoriasis	1.56e-05	0.00019	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—LEP—psoriasis	1.56e-05	0.00019	CbGpPWpGaD
Doxorubicin—Dizziness—Triamcinolone—psoriasis	1.55e-05	8.57e-05	CcSEcCtD
Doxorubicin—Anaphylactic shock—Methotrexate—psoriasis	1.55e-05	8.56e-05	CcSEcCtD
Doxorubicin—Infection—Methotrexate—psoriasis	1.54e-05	8.5e-05	CcSEcCtD
Doxorubicin—Feeling abnormal—Prednisone—psoriasis	1.53e-05	8.44e-05	CcSEcCtD
Doxorubicin—Asthenia—Betamethasone—psoriasis	1.53e-05	8.44e-05	CcSEcCtD
Doxorubicin—Asthenia—Dexamethasone—psoriasis	1.53e-05	8.44e-05	CcSEcCtD
Doxorubicin—ABCC3—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.52e-05	0.000186	CbGpPWpGaD
Doxorubicin—Nervous system disorder—Methotrexate—psoriasis	1.52e-05	8.39e-05	CcSEcCtD
Doxorubicin—Thrombocytopenia—Methotrexate—psoriasis	1.52e-05	8.38e-05	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Prednisone—psoriasis	1.52e-05	8.38e-05	CcSEcCtD
Doxorubicin—Nausea—Prednisolone—psoriasis	1.52e-05	8.37e-05	CcSEcCtD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	1.51e-05	0.000184	CbGpPWpGaD
Doxorubicin—Pruritus—Dexamethasone—psoriasis	1.51e-05	8.32e-05	CcSEcCtD
Doxorubicin—Pruritus—Betamethasone—psoriasis	1.51e-05	8.32e-05	CcSEcCtD
Doxorubicin—Skin disorder—Methotrexate—psoriasis	1.51e-05	8.31e-05	CcSEcCtD
Doxorubicin—Hyperhidrosis—Methotrexate—psoriasis	1.5e-05	8.28e-05	CcSEcCtD
Doxorubicin—NOS1—Hemostasis—TP53—psoriasis	1.5e-05	0.000183	CbGpPWpGaD
Doxorubicin—NOS2—Hemostasis—VEGFA—psoriasis	1.49e-05	0.000182	CbGpPWpGaD
Doxorubicin—Vomiting—Triamcinolone—psoriasis	1.49e-05	8.24e-05	CcSEcCtD
Doxorubicin—ABCB1—Allograft Rejection—VEGFA—psoriasis	1.49e-05	0.000181	CbGpPWpGaD
Doxorubicin—Nausea—Hydrocortisone—psoriasis	1.48e-05	8.18e-05	CcSEcCtD
Doxorubicin—Rash—Triamcinolone—psoriasis	1.48e-05	8.17e-05	CcSEcCtD
Doxorubicin—ABCB11—Metabolism—CARM1—psoriasis	1.48e-05	0.000181	CbGpPWpGaD
Doxorubicin—TOP2A—Circadian rythm related genes—IL6—psoriasis	1.48e-05	0.000181	CbGpPWpGaD
Doxorubicin—Dermatitis—Triamcinolone—psoriasis	1.48e-05	8.17e-05	CcSEcCtD
Doxorubicin—Anorexia—Methotrexate—psoriasis	1.48e-05	8.16e-05	CcSEcCtD
Doxorubicin—Urticaria—Prednisone—psoriasis	1.47e-05	8.14e-05	CcSEcCtD
Doxorubicin—Headache—Triamcinolone—psoriasis	1.47e-05	8.12e-05	CcSEcCtD
Doxorubicin—CYP2B6—Metabolism—CYP2S1—psoriasis	1.47e-05	0.000179	CbGpPWpGaD
Doxorubicin—Abdominal pain—Prednisone—psoriasis	1.47e-05	8.1e-05	CcSEcCtD
Doxorubicin—Body temperature increased—Prednisone—psoriasis	1.47e-05	8.1e-05	CcSEcCtD
Doxorubicin—Diarrhoea—Betamethasone—psoriasis	1.46e-05	8.05e-05	CcSEcCtD
Doxorubicin—Diarrhoea—Dexamethasone—psoriasis	1.46e-05	8.05e-05	CcSEcCtD
Doxorubicin—RALBP1—Signaling Pathways—NFKBIA—psoriasis	1.45e-05	0.000177	CbGpPWpGaD
Doxorubicin—Hypotension—Methotrexate—psoriasis	1.45e-05	8e-05	CcSEcCtD
Doxorubicin—NOS2—Disease—HLA-A—psoriasis	1.44e-05	0.000175	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—CARM1—psoriasis	1.42e-05	0.000173	CbGpPWpGaD
Doxorubicin—Musculoskeletal discomfort—Methotrexate—psoriasis	1.41e-05	7.8e-05	CcSEcCtD
Doxorubicin—Dizziness—Betamethasone—psoriasis	1.41e-05	7.78e-05	CcSEcCtD
Doxorubicin—Dizziness—Dexamethasone—psoriasis	1.41e-05	7.78e-05	CcSEcCtD
Doxorubicin—Insomnia—Methotrexate—psoriasis	1.4e-05	7.74e-05	CcSEcCtD
Doxorubicin—Nausea—Triamcinolone—psoriasis	1.39e-05	7.7e-05	CcSEcCtD
Doxorubicin—Paraesthesia—Methotrexate—psoriasis	1.39e-05	7.69e-05	CcSEcCtD
Doxorubicin—ABCB11—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.38e-05	0.000169	CbGpPWpGaD
Doxorubicin—Dyspnoea—Methotrexate—psoriasis	1.38e-05	7.63e-05	CcSEcCtD
Doxorubicin—Somnolence—Methotrexate—psoriasis	1.38e-05	7.61e-05	CcSEcCtD
Doxorubicin—NQO1—Metabolism—CAT—psoriasis	1.38e-05	0.000168	CbGpPWpGaD
Doxorubicin—AURKA—Cell Cycle—TP53—psoriasis	1.37e-05	0.000168	CbGpPWpGaD
Doxorubicin—Hypersensitivity—Prednisone—psoriasis	1.37e-05	7.55e-05	CcSEcCtD
Doxorubicin—Dyspepsia—Methotrexate—psoriasis	1.36e-05	7.53e-05	CcSEcCtD
Doxorubicin—NOS1—Disease—TYK2—psoriasis	1.36e-05	0.000166	CbGpPWpGaD
Doxorubicin—Vomiting—Dexamethasone—psoriasis	1.35e-05	7.48e-05	CcSEcCtD
Doxorubicin—Vomiting—Betamethasone—psoriasis	1.35e-05	7.48e-05	CcSEcCtD
Doxorubicin—Decreased appetite—Methotrexate—psoriasis	1.35e-05	7.44e-05	CcSEcCtD
Doxorubicin—Rash—Dexamethasone—psoriasis	1.34e-05	7.42e-05	CcSEcCtD
Doxorubicin—Rash—Betamethasone—psoriasis	1.34e-05	7.42e-05	CcSEcCtD
Doxorubicin—Dermatitis—Dexamethasone—psoriasis	1.34e-05	7.41e-05	CcSEcCtD
Doxorubicin—Dermatitis—Betamethasone—psoriasis	1.34e-05	7.41e-05	CcSEcCtD
Doxorubicin—NOS2—Disease—APOE—psoriasis	1.34e-05	0.000164	CbGpPWpGaD
Doxorubicin—Gastrointestinal disorder—Methotrexate—psoriasis	1.34e-05	7.39e-05	CcSEcCtD
Doxorubicin—Fatigue—Methotrexate—psoriasis	1.34e-05	7.38e-05	CcSEcCtD
Doxorubicin—Headache—Dexamethasone—psoriasis	1.33e-05	7.37e-05	CcSEcCtD
Doxorubicin—Headache—Betamethasone—psoriasis	1.33e-05	7.37e-05	CcSEcCtD
Doxorubicin—Asthenia—Prednisone—psoriasis	1.33e-05	7.35e-05	CcSEcCtD
Doxorubicin—AKR1C3—Metabolism—CAT—psoriasis	1.33e-05	0.000162	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.33e-05	0.000162	CbGpPWpGaD
Doxorubicin—Pain—Methotrexate—psoriasis	1.33e-05	7.32e-05	CcSEcCtD
Doxorubicin—AKR1C3—Disease—HLA-A—psoriasis	1.32e-05	0.000161	CbGpPWpGaD
Doxorubicin—Pruritus—Prednisone—psoriasis	1.31e-05	7.25e-05	CcSEcCtD
Doxorubicin—Feeling abnormal—Methotrexate—psoriasis	1.28e-05	7.05e-05	CcSEcCtD
Doxorubicin—ABCB1—Allograft Rejection—TNF—psoriasis	1.27e-05	0.000155	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—NDUFA5—psoriasis	1.27e-05	0.000155	CbGpPWpGaD
Doxorubicin—Diarrhoea—Prednisone—psoriasis	1.27e-05	7.01e-05	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Methotrexate—psoriasis	1.27e-05	7e-05	CcSEcCtD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	1.27e-05	0.000155	CbGpPWpGaD
Doxorubicin—Nausea—Betamethasone—psoriasis	1.27e-05	6.99e-05	CcSEcCtD
Doxorubicin—Nausea—Dexamethasone—psoriasis	1.27e-05	6.99e-05	CcSEcCtD
Doxorubicin—XDH—Metabolism—CAT—psoriasis	1.23e-05	0.000151	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—APOE—psoriasis	1.23e-05	0.00015	CbGpPWpGaD
Doxorubicin—Urticaria—Methotrexate—psoriasis	1.23e-05	6.8e-05	CcSEcCtD
Doxorubicin—NOS1—Disease—CD4—psoriasis	1.23e-05	0.00015	CbGpPWpGaD
Doxorubicin—Dizziness—Prednisone—psoriasis	1.23e-05	6.77e-05	CcSEcCtD
Doxorubicin—Body temperature increased—Methotrexate—psoriasis	1.23e-05	6.77e-05	CcSEcCtD
Doxorubicin—Abdominal pain—Methotrexate—psoriasis	1.23e-05	6.77e-05	CcSEcCtD
Doxorubicin—CYP2D6—Metabolism—NDUFA5—psoriasis	1.2e-05	0.000146	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.19e-05	0.000146	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—TYK2—psoriasis	1.19e-05	0.000145	CbGpPWpGaD
Doxorubicin—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	1.18e-05	0.000144	CbGpPWpGaD
Doxorubicin—Vomiting—Prednisone—psoriasis	1.18e-05	6.51e-05	CcSEcCtD
Doxorubicin—Rash—Prednisone—psoriasis	1.17e-05	6.46e-05	CcSEcCtD
Doxorubicin—AKR1C3—Signaling Pathways—SOCS1—psoriasis	1.17e-05	0.000143	CbGpPWpGaD
Doxorubicin—Dermatitis—Prednisone—psoriasis	1.17e-05	6.45e-05	CcSEcCtD
Doxorubicin—Headache—Prednisone—psoriasis	1.16e-05	6.42e-05	CcSEcCtD
Doxorubicin—NOS3—Hemostasis—VEGFA—psoriasis	1.16e-05	0.000142	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.15e-05	0.000141	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—NOS2—psoriasis	1.15e-05	0.00014	CbGpPWpGaD
Doxorubicin—Hypersensitivity—Methotrexate—psoriasis	1.14e-05	6.31e-05	CcSEcCtD
Doxorubicin—NOS2—Hemostasis—TP53—psoriasis	1.13e-05	0.000138	CbGpPWpGaD
Doxorubicin—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	1.13e-05	0.000138	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—CAT—psoriasis	1.12e-05	0.000137	CbGpPWpGaD
Doxorubicin—NOS3—Disease—HLA-A—psoriasis	1.12e-05	0.000136	CbGpPWpGaD
Doxorubicin—Asthenia—Methotrexate—psoriasis	1.11e-05	6.14e-05	CcSEcCtD
Doxorubicin—ABCC1—Metabolism—CARM1—psoriasis	1.11e-05	0.000136	CbGpPWpGaD
Doxorubicin—Nausea—Prednisone—psoriasis	1.1e-05	6.08e-05	CcSEcCtD
Doxorubicin—Pruritus—Methotrexate—psoriasis	1.1e-05	6.06e-05	CcSEcCtD
Doxorubicin—ABCB1—Metabolism—CYP2S1—psoriasis	1.08e-05	0.000132	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—CARM1—psoriasis	1.08e-05	0.000131	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—APOE—psoriasis	1.07e-05	0.000131	CbGpPWpGaD
Doxorubicin—Diarrhoea—Methotrexate—psoriasis	1.06e-05	5.86e-05	CcSEcCtD
Doxorubicin—YWHAG—Cell Cycle—TP53—psoriasis	1.04e-05	0.000127	CbGpPWpGaD
Doxorubicin—NOS3—Disease—APOE—psoriasis	1.04e-05	0.000127	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.04e-05	0.000127	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—CXCL8—psoriasis	1.03e-05	0.000126	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—APOE—psoriasis	1.03e-05	0.000126	CbGpPWpGaD
Doxorubicin—TOP2A—Methyltestosterone—Hydrocortisone—psoriasis	1.03e-05	0.00283	CbGdCrCtD
Doxorubicin—Dizziness—Methotrexate—psoriasis	1.03e-05	5.66e-05	CcSEcCtD
Doxorubicin—NOS2—Disease—TYK2—psoriasis	1.02e-05	0.000125	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—CYP2S1—psoriasis	1.02e-05	0.000125	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.01e-05	0.000123	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—SOCS1—psoriasis	9.88e-06	0.000121	CbGpPWpGaD
Doxorubicin—Vomiting—Methotrexate—psoriasis	9.86e-06	5.44e-05	CcSEcCtD
Doxorubicin—ABCG2—Metabolism—CARM1—psoriasis	9.78e-06	0.000119	CbGpPWpGaD
Doxorubicin—Rash—Methotrexate—psoriasis	9.77e-06	5.4e-05	CcSEcCtD
Doxorubicin—Dermatitis—Methotrexate—psoriasis	9.76e-06	5.39e-05	CcSEcCtD
Doxorubicin—Headache—Methotrexate—psoriasis	9.71e-06	5.36e-05	CcSEcCtD
Doxorubicin—NOS3—Disease—NOS2—psoriasis	9.7e-06	0.000118	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—JUN—psoriasis	9.62e-06	0.000117	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—APOE—psoriasis	9.59e-06	0.000117	CbGpPWpGaD
Doxorubicin—NOS1—Disease—STAT3—psoriasis	9.5e-06	0.000116	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—TYK2—psoriasis	9.41e-06	0.000115	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—PPARG—psoriasis	9.32e-06	0.000114	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—NFKB1—psoriasis	9.26e-06	0.000113	CbGpPWpGaD
Doxorubicin—NOS2—Disease—CD4—psoriasis	9.26e-06	0.000113	CbGpPWpGaD
Doxorubicin—Nausea—Methotrexate—psoriasis	9.21e-06	5.08e-05	CcSEcCtD
Doxorubicin—ABCB11—Metabolism—CAT—psoriasis	9.1e-06	0.000111	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—PPARG—psoriasis	8.99e-06	0.00011	CbGpPWpGaD
Doxorubicin—TOP2A—Methyltestosterone—Prednisone—psoriasis	8.85e-06	0.00244	CbGdCrCtD
Doxorubicin—NOS3—Hemostasis—TP53—psoriasis	8.77e-06	0.000107	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—CAT—psoriasis	8.73e-06	0.000106	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—APOE—psoriasis	8.72e-06	0.000106	CbGpPWpGaD
Doxorubicin—TOP2A—Methyltestosterone—Prednisolone—psoriasis	8.64e-06	0.00238	CbGdCrCtD
Doxorubicin—AKR1C3—Signaling Pathways—LEP—psoriasis	8.63e-06	0.000105	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—APOE—psoriasis	8.63e-06	0.000105	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—CD4—psoriasis	8.51e-06	0.000104	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—VEGFA—psoriasis	8.41e-06	0.000103	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	8.4e-06	0.000102	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—PPARG—psoriasis	8.36e-06	0.000102	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—STAT3—psoriasis	8.32e-06	0.000102	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	8.08e-06	9.86e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—NFKBIA—psoriasis	8.04e-06	9.81e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—TYK2—psoriasis	7.95e-06	9.7e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—NDUFA5—psoriasis	7.85e-06	9.58e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—PPARG—psoriasis	7.6e-06	9.27e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	7.34e-06	8.95e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—LEP—psoriasis	7.29e-06	8.9e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—APOE—psoriasis	7.29e-06	8.9e-05	CbGpPWpGaD
Doxorubicin—TOP2A—Cell Cycle—TP53—psoriasis	7.29e-06	8.89e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—CD4—psoriasis	7.19e-06	8.77e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—CARM1—psoriasis	7.17e-06	8.75e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—STAT3—psoriasis	7.17e-06	8.74e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—APOE—psoriasis	7.07e-06	8.63e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—CAT—psoriasis	6.84e-06	8.34e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—HLA-A—psoriasis	6.8e-06	8.29e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—NFKBIA—psoriasis	6.79e-06	8.29e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—APOE—psoriasis	6.78e-06	8.27e-05	CbGpPWpGaD
Doxorubicin—TOP2A—Norethindrone—Hydrocortisone—psoriasis	6.7e-06	0.00184	CbGdCrCtD
Doxorubicin—CYP3A4—Metabolism—CYP2S1—psoriasis	6.67e-06	8.14e-05	CbGpPWpGaD
Doxorubicin—NOS1—Disease—IL6—psoriasis	6.64e-06	8.1e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—CAT—psoriasis	6.61e-06	8.07e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—TYK2—psoriasis	6.59e-06	8.04e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—STAT3—psoriasis	6.59e-06	8.04e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—TP53—psoriasis	6.35e-06	7.75e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—APOE—psoriasis	6.34e-06	7.74e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	6.29e-06	7.67e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PPARG—psoriasis	6.16e-06	7.52e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—CAT—psoriasis	6.02e-06	7.34e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—NOS2—psoriasis	5.91e-06	7.21e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PPARG—psoriasis	5.91e-06	7.21e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—IL6—psoriasis	5.81e-06	7.09e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CXCL8—psoriasis	5.73e-06	7e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—TYK2—psoriasis	5.56e-06	6.79e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—STAT3—psoriasis	5.56e-06	6.79e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	5.54e-06	6.76e-05	CbGpPWpGaD
Doxorubicin—TOP2A—Levonorgestrel—Hydrocortisone—psoriasis	5.33e-06	0.00147	CbGdCrCtD
Doxorubicin—AKR1C3—Signaling Pathways—JUN—psoriasis	5.33e-06	6.51e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—APOE—psoriasis	5.31e-06	6.48e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—CARM1—psoriasis	5.29e-06	6.45e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—APOE—psoriasis	5.14e-06	6.27e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—NFKB1—psoriasis	5.13e-06	6.26e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—IL6—psoriasis	5.01e-06	6.11e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—CARM1—psoriasis	4.98e-06	6.08e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CXCL8—psoriasis	4.85e-06	5.91e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—TYK2—psoriasis	4.84e-06	5.91e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—APOE—psoriasis	4.68e-06	5.71e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—VEGFA—psoriasis	4.66e-06	5.68e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PPARG—psoriasis	4.63e-06	5.65e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—STAT3—psoriasis	4.61e-06	5.63e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—IL6—psoriasis	4.6e-06	5.61e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—JUN—psoriasis	4.5e-06	5.5e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PPARG—psoriasis	4.48e-06	5.46e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—CAT—psoriasis	4.41e-06	5.38e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—CD4—psoriasis	4.38e-06	5.34e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—NFKB1—psoriasis	4.34e-06	5.29e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PPARG—psoriasis	4.07e-06	4.97e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—VEGFA—psoriasis	3.94e-06	4.8e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—STAT3—psoriasis	3.9e-06	4.75e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—IL6—psoriasis	3.89e-06	4.74e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—TP53—psoriasis	3.52e-06	4.29e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—APOE—psoriasis	3.43e-06	4.18e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—STAT3—psoriasis	3.39e-06	4.14e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CARM1—psoriasis	3.26e-06	3.98e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—CAT—psoriasis	3.25e-06	3.97e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—IL6—psoriasis	3.22e-06	3.93e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—CAT—psoriasis	3.07e-06	3.74e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PPARG—psoriasis	2.99e-06	3.64e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—TP53—psoriasis	2.97e-06	3.63e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—IL6—psoriasis	2.72e-06	3.32e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—APOE—psoriasis	2.53e-06	3.08e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—APOE—psoriasis	2.38e-06	2.91e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—IL6—psoriasis	2.37e-06	2.89e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PPARG—psoriasis	2.2e-06	2.69e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PPARG—psoriasis	2.07e-06	2.53e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CAT—psoriasis	2e-06	2.45e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—APOE—psoriasis	1.56e-06	1.9e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PPARG—psoriasis	1.36e-06	1.66e-05	CbGpPWpGaD
